Loading...
XNASAXGN
Market cap736mUSD
Dec 26, Last price  
16.73USD
1D
2.89%
1Q
21.32%
Jan 2017
85.89%
Name

AxoGen Inc

Chart & Performance

D1W1MN
XNAS:AXGN chart
P/E
P/S
4.63
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
2.92%
Rev. gr., 5y
13.63%
Revenues
159m
+14.74%
1,065,000443,352126,660100,43172,71124,911,37691,2734,849,4707,691,70410,947,36116,817,40327,331,09241,107,53860,426,39583,937,000106,712,000112,300,000127,358,000138,584,000159,012,000
Net income
-22m
L-20.56%
2,296,679-530,612-367,182-748,980-1,040,70915,046,332-1,316,299-9,219,220-9,417,958-14,556,885-17,710,476-13,356,425-14,411,144-10,445,462-22,397,000-29,122,000-24,802,000-28,063,000-27,335,000-21,716,000
CFO
-6m
L-64.42%
878,839-709,618-28,793-466,947-470,16415,441,941-2,429,661-7,079,290-8,661,858-10,444,758-10,451,059-13,051,819-11,204,442-9,237,599-17,862,000-19,872,000-9,626,000-13,405,000-16,066,000-5,716,000
Dividend
Jan 27, 20101 USD/sh
Earnings
Apr 30, 2025

Profile

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
IPO date
Dec 17, 1986
Employees
394
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
159,012
14.74%
138,584
8.81%
127,358
13.41%
Cost of revenue
180,474
168,291
152,774
Unusual Expense (Income)
NOPBT
(21,462)
(29,707)
(25,416)
NOPBT Margin
Operating Taxes
(1,613)
1,078
Tax Rate
NOPAT
(21,462)
(28,094)
(26,494)
Net income
(21,716)
-20.56%
(27,335)
-2.59%
(28,063)
13.15%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,964
1,806
5,467
BB yield
-0.67%
-0.43%
-1.42%
Debt
Debt current
1,547
1,310
1,834
Long-term debt
90,434
87,832
88,251
Deferred revenue
Other long-term liabilities
2,987
4,518
5,562
Net debt
60,957
40,353
5,999
Cash flow
Cash from operating activities
(5,716)
(16,066)
(13,405)
CAPEX
(13,872)
(21,253)
(28,400)
Cash from investing activities
19,253
(3,200)
(23,649)
Cash from financing activities
1,954
1,794
20,452
FCF
(39,596)
(49,980)
(52,313)
Balance
Cash
31,024
48,789
84,086
Long term investments
Excess cash
23,073
41,860
77,718
Stockholders' equity
(280,865)
(259,156)
(230,215)
Invested Capital
448,809
432,100
415,780
ROIC
ROCE
EV
Common stock shares outstanding
42,879
42,083
41,215
Price
6.83
-31.56%
9.98
6.51%
9.37
-47.65%
Market cap
292,860
-30.27%
419,990
8.75%
386,185
-46.02%
EV
353,817
460,343
392,184
EBITDA
(15,909)
(24,854)
(20,675)
EV/EBITDA
Interest
2,835
624
1,356
Interest/NOPBT